Tamer Hudali, MD
Pulmonary Disease · Hattiesburg, MSNPI 1770863615
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.7%), education and consulting fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Intuitive Surgical at 28.9% of the total. 2025 is the largest year on record at $5,695, more than ten times the $95 reported in 2019.
Across 352 payments — averaging $41.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Sanofi$3K
- AstraZeneca$1K
- GSK$866
- Baxter Healthcare$517
- Boehringer Ingelheim$490
- plus $4K from 31 others
What the payments were for
- Consulting fees$2,53617%
- Travel & lodging$8706%
- Food & beverage$7,94755%
- Education$3,18422%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 9 | $4,204 |
| Sanofi | 27 | $3,230 |
| AstraZeneca | 50 | $1,329 |
| GSK | 70 | $866 |
| Baxter Healthcare | 24 | $517 |
| Boehringer Ingelheim | 22 | $490 |
| Regeneron Healthcare Solutions, Inc. | 17 | $471 |
| Actelion Pharmaceuticals US, Inc. | 13 | $374 |
| Regeneron | 3 | $310 |
| Verona Pharma, Inc. | 17 | $308 |
| Mylan Specialty L.p. | 10 | $274 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $248 |
| Inspire Medical Systems, Inc. | 4 | $197 |
| Amgen | 11 | $195 |
| Insmed, Inc. | 8 | $194 |
| Edwards Lifesciences | 2 | $182 |
| Viatris Specialty LLC | 10 | $177 |
| Grifols USA, LLC | 8 | $176 |
| Novo Nordisk | 1 | $124 |
| United Therapeutics Corporation | 5 | $123 |
| Electromed, Inc. | 4 | $111 |
| Philips North America LLC | 3 | $60 |
| Merck | 2 | $46 |
| Inogen, Inc. | 3 | $40 |
| Vifor Pharma, Inc. | 2 | $35 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Harmony Biosciences LLC | 1 | $28 |
| Johnson & Johnson | 1 | $27 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Vapotherm Inc | 1 | $22 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Novartis | 1 | $15 |
| Boston Scientific | 1 | $14 |
| Pfizer | 1 | $13 |
| Inari Medical, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$932
- FASENRA$461
- AIRSUPRA$461
- TEZSPIRE$461
- DUPIXENT$440
- SAPIEN 3 Ultra RESILIA$148
- Ozempic$124
- BREZTRI$121
- Yupelri$117
- Hillrom - Life 2000 Ventilation System$105
How this compares
$14,537 in reported general payments places this provider in the 80th percentile of 101 pulmonary disease providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 33 | $433,210 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 243 | $194,882 |
| Fasenra PenBenralizumab | 23 | $139,016 |
| TezspireTezepelumab-Ekko | 15 | $104,668 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 132 | $89,987 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 113 | $53,011 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 79 | $46,482 |
| Spiriva RespimatTiotropium Bromide | 47 | $27,234 |
| SymbicortBudesonide/Formoterol Fumarate | 62 | $14,597 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $6,051 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $5,686 |
| Epinephrine | 31 | $4,980 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 29 | $4,312 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 21 | $3,955 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $3,394 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $490 | $512,613171 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $866 | $253,944373 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $1,329 | $209,252209 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 pulmonary disease providers in Mississippi.
Other pulmonary disease in Hattiesburg
- L AldredHattiesburg$76K
- Walid YounisHattiesburg$15K
- Michael RaggioHattiesburg$11K
- Lewis NeeseHattiesburg$9K
- Kevin KinlochHattiesburg$6K
- Randolph RossHattiesburg$5K
- Charles McCollumHattiesburg$4K
- Andrew RognessHattiesburg$4K
- William FrazierCanton$809K
- Demondes HaynesJackson$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.